MAPS Bulletin Autumn 1990: Vol. 01, No. 3 What and Who is MAPS? Download this entire issue or browse individual articles by title below. What and Who is MAPS? Rick Doblin, Ph.D. The Two Functions of MAPS Rick Doblin, Ph.D. Thoughts About the Ethics of Animal Research Rick Doblin, Ph.D. MDMA Neurotoxicity Overview Rick Doblin, Ph.D. Preliminary Findings from Primate Neurotoxicity Studies Rick Doblin, Ph.D. Dr. Nichols Confirms that Prozac Blocks MDMA Neurotoxicity Rick Doblin, Ph.D. Requested – Subjective Reports of the Prozac / MDMA Combinations Rick Doblin, Ph.D. Findings From the Two NIDA-Funded MDMA Human Studies Rick Doblin, Ph.D. A Call for Volunteers for the Johns Hopkins MDMA Human Neurotoxicity Study Rick Doblin, Ph.D. Update on Swiss Psychedelic Research Rick Doblin, Ph.D. Unsuccessful MAPS Attempts at Collaborative Research Rick Doblin, Ph.D. Swiss Psychedelic Usage Halted – Resumption Possible But Not Certain Rick Doblin, Ph.D. New Opportunities for MDMA Research in Czechoslovakia Rick Doblin, Ph.D. The MAPS International Research Methodology Conference Rick Doblin, Ph.D. Pharmaceutical Companies Study the Market For Psychedelics Rick Doblin, Ph.D. MAPS’ Research Agenda and Financial Requests Rick Doblin, Ph.D.